Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma

Ibrutinib (Imbruvica®), a small-drug inhibitor of Bruton tyrosine kinase (BTK), is currently undergoing clinical testing in patients with multiple myeloma (MM), yet important questions on the role of BTK in myeloma biology and treatment are outstanding. Using flow-sorted side population (SP) cells f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Yang, Ye, Shi, Jumei, Gu, Zhimin, Salama, Mohamed E, Das, Satyabrata, Wendlandt, Erik, Xu, Hongwei, Huang, Junwei, Tao, Yi, Hao, Mu, Franqui, Reinaldo, Levasseur, Dana, Janz, Siegfried, Tricot, Guido, Zhan, Fenghuang
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4384656/
https://ncbi.nlm.nih.gov/pubmed/25589346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-2362
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados